
IBRO Neuroscience Reports, Journal Year: 2024, Volume and Issue: 18, P. 96 - 119
Published: Dec. 20, 2024
Cannabis sativa is recognized for its chemical diversity and therapeutic potential, particularly in addressing neurodegenerative diseases such as Alzheimer's disease (AD). Given the complexity of AD, where single-target therapies often prove inadequate, a multi-target approach utilizing cannabis-derived compounds may offer promising alternatives. This review first highlights cannabis by categorizing into cannabinoids non-cannabinoids. It then examines studies investigating effects these on AD-related pathological features. By synthesizing existing knowledge, identifying research gaps, facilitating comparative analysis, this aims to advance future understanding. underscores cannabis's potential strategy contributing valuable insights ongoing scientific discussions.
Language: Английский